23 research outputs found
Indications for the Nonexistence of Three-Neutron Resonances near the Physical Region
The pending question of the existence of three-neutron resonances near the
physical energy region is reconsidered. Finite rank neutron-neutron forces are
used in Faddeev equations, which are analytically continued into the unphysical
energy sheet below the positive real energy axis. The trajectories of the
three-neutron S-matrix poles in the states of total angular momenta and parity
J^\pi=1/2 +- and J^\pi= 3/2 +- are traced out as a function of artificial
enhancement factors of the neutron-neutron forces. The final positions of the
S-matrix poles removing the artificial factors are found in all cases to be far
away from the positive real energy axis, which provides a strong indication for
the nonexistence of nearby three-neutron resonances. The pole trajectories
close to the threshold E=0 are also predicted out of auxiliary generated
three-neutron bound state energies using the Pad\'e method and agree very well
with the directly calculated ones.Comment: 20 pages, 7 Postscript figures, fig.1 is corrected, uses relax.st
Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer: study protocol of a multicentre, open-label, parallel-arms, randomized controlled study (PelvEx II)
Background A resection with clear margins (R0 resection) is the most important prognostic factor in patients with locally recurrent rectal cancer (LRRC). However, this is achieved in only 60 per cent of patients. The aim of this study is to investigate whether the addition of induction chemotherapy to neoadjuvant chemo(re)irradiation improves the R0 resection rate in LRRC. Methods This multicentre, international, open-label, phase III, parallel-arms study will enrol 364 patients with resectable LRRC after previous partial or total mesorectal resection without synchronous distant metastases or recent chemo- and/or radiotherapy treatment. Patients will be randomized to receive either induction chemotherapy (three 3-week cycles of CAPOX (capecitabine, oxaliplatin), four 2-week cycles of FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) or FOLFORI (5-fluorouracil, leucovorin, irinotecan)) followed by neoadjuvant chemoradiotherapy and surgery (experimental arm) or neoadjuvant chemoradiotherapy and surgery alone (control arm). Tumours will be restaged using MRI and, in the experimental arm, a further cycle of CAPOX or two cycles of FOLFOX/FOLFIRI will be administered before chemoradiotherapy in case of stable or responsive disease. The radiotherapy dose will be 25 Ă 2.0 Gy or 28 Ă 1.8âGy in radiotherapy-naive patients, and 15 Ă 2.0âGy in previously irradiated patients. The concomitant chemotherapy agent will be capecitabine administered twice daily at a dose of 825âmg/m2 on radiotherapy days. The primary endpoint of the study is the R0 resection rate. Secondary endpoints are long-term oncological outcomes, radiological and pathological response, toxicity, postoperative complications, costs, and quality of life. Discussion This trial protocol describes the PelvEx II study. PelvEx II, designed as a multicentre, open-label, phase III, parallel-arms study, is the first randomized study to compare induction chemotherapy followed by neoadjuvant chemo(re)irradiation and surgery with neoadjuvant chemo(re)irradiation and surgery alone in patients with locally recurrent rectal cancer, with the aim of improving the number of R0 resections